RU2012110221A - Аптамеры к ингибитору пути тканевого фактора и их использование в качестве терапевтических агентов при нарушениях свертываемости - Google Patents
Аптамеры к ингибитору пути тканевого фактора и их использование в качестве терапевтических агентов при нарушениях свертываемости Download PDFInfo
- Publication number
- RU2012110221A RU2012110221A RU2012110221/10A RU2012110221A RU2012110221A RU 2012110221 A RU2012110221 A RU 2012110221A RU 2012110221/10 A RU2012110221/10 A RU 2012110221/10A RU 2012110221 A RU2012110221 A RU 2012110221A RU 2012110221 A RU2012110221 A RU 2012110221A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- acid residues
- aptamer
- seq
- tfpi
- Prior art date
Links
- 108091023037 Aptamer Proteins 0.000 title claims abstract 49
- 239000003112 inhibitor Substances 0.000 title claims 7
- 108010000499 Thromboplastin Proteins 0.000 title claims 5
- 102000002262 Thromboplastin Human genes 0.000 title claims 5
- 239000003814 drug Substances 0.000 title claims 3
- 229940124597 therapeutic agent Drugs 0.000 title claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 33
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims abstract 30
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims abstract 30
- 239000002773 nucleotide Substances 0.000 claims abstract 28
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims abstract 16
- 150000003839 salts Chemical class 0.000 claims abstract 12
- 238000006467 substitution reaction Methods 0.000 claims abstract 9
- 239000005547 deoxyribonucleotide Substances 0.000 claims abstract 8
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 8
- 239000000126 substance Substances 0.000 claims abstract 6
- 101000653189 Homo sapiens Tissue factor pathway inhibitor Proteins 0.000 claims abstract 5
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 230000021615 conjugation Effects 0.000 claims abstract 4
- 230000002163 immunogen Effects 0.000 claims abstract 4
- 238000012986 modification Methods 0.000 claims abstract 4
- 230000004048 modification Effects 0.000 claims abstract 4
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 4
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 3
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 2
- 125000000837 carbohydrate group Chemical group 0.000 claims abstract 2
- 238000007385 chemical modification Methods 0.000 claims abstract 2
- 238000010494 dissociation reaction Methods 0.000 claims abstract 2
- 230000005593 dissociations Effects 0.000 claims abstract 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical compound OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000002634 lipophilic molecules Chemical class 0.000 claims abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract 2
- 239000010452 phosphate Substances 0.000 claims abstract 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims abstract 2
- 125000000539 amino acid group Chemical group 0.000 claims 55
- 238000000034 method Methods 0.000 claims 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 230000037361 pathway Effects 0.000 claims 6
- 206010053567 Coagulopathies Diseases 0.000 claims 5
- 208000009292 Hemophilia A Diseases 0.000 claims 4
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 3
- 208000032843 Hemorrhage Diseases 0.000 claims 3
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 claims 3
- 208000015294 blood coagulation disease Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000015271 coagulation Effects 0.000 claims 3
- 238000005345 coagulation Methods 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 208000009429 hemophilia B Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108010094028 Prothrombin Proteins 0.000 claims 2
- 102100027378 Prothrombin Human genes 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000009852 coagulant defect Effects 0.000 claims 2
- 201000007219 factor XI deficiency Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229940039716 prothrombin Drugs 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 238000013169 thromboelastometry Methods 0.000 claims 2
- 229940035893 uracil Drugs 0.000 claims 2
- WKKCYLSCLQVWFD-UHFFFAOYSA-N 1,2-dihydropyrimidin-4-amine Chemical compound N=C1NCNC=C1 WKKCYLSCLQVWFD-UHFFFAOYSA-N 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000033131 Congenital factor II deficiency Diseases 0.000 claims 1
- 206010016077 Factor IX deficiency Diseases 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108700009202 Plasminogen Activator Inhibitor-1 Deficiency Proteins 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000000667 alpha-2-plasmin inhibitor deficiency Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000000544 articulatio talocruralis Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 108090001015 cancer procoagulant Proteins 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 108700017143 congenital Anti-plasmin deficiency Proteins 0.000 claims 1
- 208000011664 congenital factor XI deficiency Diseases 0.000 claims 1
- 208000014522 congenital prothrombin deficiency Diseases 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000002310 elbow joint Anatomy 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000002085 hemarthrosis Diseases 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 210000000629 knee joint Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000007106 menorrhagia Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000017570 negative regulation of blood coagulation Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23493909P | 2009-08-18 | 2009-08-18 | |
| US61/234,939 | 2009-08-18 | ||
| US35337410P | 2010-06-10 | 2010-06-10 | |
| US61/353,374 | 2010-06-10 | ||
| US36636210P | 2010-07-21 | 2010-07-21 | |
| US61/366,362 | 2010-07-21 | ||
| US36776610P | 2010-07-26 | 2010-07-26 | |
| US61/367,766 | 2010-07-26 | ||
| PCT/US2010/045797 WO2011022427A1 (en) | 2009-08-18 | 2010-08-17 | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012110221A true RU2012110221A (ru) | 2013-09-27 |
Family
ID=43607310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012110221/10A RU2012110221A (ru) | 2009-08-18 | 2010-08-17 | Аптамеры к ингибитору пути тканевого фактора и их использование в качестве терапевтических агентов при нарушениях свертываемости |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8252913B2 (enExample) |
| EP (1) | EP2467167B1 (enExample) |
| JP (1) | JP2013502218A (enExample) |
| KR (1) | KR20120061086A (enExample) |
| CN (1) | CN102869385A (enExample) |
| AU (1) | AU2010284329B2 (enExample) |
| BR (1) | BR112012003806A2 (enExample) |
| CA (1) | CA2770762A1 (enExample) |
| CO (1) | CO6531414A2 (enExample) |
| ES (1) | ES2655589T3 (enExample) |
| IL (1) | IL218048A0 (enExample) |
| IN (1) | IN2012DN01984A (enExample) |
| MX (1) | MX2012002133A (enExample) |
| NZ (1) | NZ598557A (enExample) |
| RU (1) | RU2012110221A (enExample) |
| SG (1) | SG178408A1 (enExample) |
| WO (1) | WO2011022427A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070166741A1 (en) | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| CN102325795B (zh) | 2008-12-22 | 2015-03-25 | 诺沃—诺迪斯克有限公司 | 针对组织因子途径抑制剂的抗体 |
| EP2673364A1 (en) * | 2011-02-11 | 2013-12-18 | Baxter International Inc | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| AU2012267270B2 (en) | 2011-06-08 | 2015-06-11 | Miedzynarodowy Instytut Biologii Molekularnej I Komorkowej | Sequence-specific engineered ribonuclease H and the method for determining the sequence preference of DNA-RNA hybrid binding proteins |
| US20130267584A1 (en) * | 2012-03-22 | 2013-10-10 | Baxter Healthcare S.A. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| DE102012020496A1 (de) | 2012-10-18 | 2014-04-24 | Charité - Universitätsmedizin Berlin | Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1 |
| WO2014205426A1 (en) * | 2013-06-21 | 2014-12-24 | Imigene, Inc. | Blood analysis |
| JP6584397B2 (ja) | 2013-07-19 | 2019-10-02 | ノヴォ ノルディスク アー／エス | 凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体 |
| EP3044334B1 (en) | 2013-09-09 | 2020-08-12 | Somalogic, Inc. | Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders |
| WO2015154090A1 (en) * | 2014-04-04 | 2015-10-08 | Bloodworks | Routine laboratory and point-of-care (poc) testing for hemostasis |
| PT3313991T (pt) * | 2015-06-23 | 2024-09-27 | Childrens Hospital Philadelphia | Fator ix modificado e composições, métodos e utilizações para transferência de genes para células, órgãos e tecidos |
| US20170232079A1 (en) * | 2015-10-06 | 2017-08-17 | Kieu Hoang | Method of manufacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv |
| WO2017094897A1 (ja) * | 2015-12-04 | 2017-06-08 | 全薬工業株式会社 | 血中滞留性を改善した抗ｉｌ－１７アプタマー |
| CN112442127A (zh) | 2019-08-29 | 2021-03-05 | 苏州康宁杰瑞生物科技有限公司 | 针对tfpi的单克隆抗体 |
| CN115792231B (zh) * | 2022-11-04 | 2023-07-25 | 中拓生物有限公司 | 一种基于凝血酶适配体调节的酶级联反应的DNase I生物传感器 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US5981471A (en) * | 1997-02-06 | 1999-11-09 | Entremed, Inc. | Compositions and methods for inhibiting cellular proliferation |
| WO1998037919A1 (en) * | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| US6426334B1 (en) * | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| DK1009413T3 (da) * | 1997-09-05 | 2007-06-11 | Univ California | Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma |
| US6410278B1 (en) * | 1998-11-09 | 2002-06-25 | Eiken Kagaku Kabushiki Kaisha | Process for synthesizing nucleic acid |
| US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
| WO2003102212A2 (en) * | 2002-05-31 | 2003-12-11 | Regents Of The University Of Minnesota | In vitro evaluation of nucleic acid ligands |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| EP1919499A2 (en) * | 2005-07-29 | 2008-05-14 | Universiteit van Maastricht | Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor |
-
2010
- 2010-08-17 SG SG2012010245A patent/SG178408A1/en unknown
- 2010-08-17 ES ES10810508.1T patent/ES2655589T3/es active Active
- 2010-08-17 MX MX2012002133A patent/MX2012002133A/es active IP Right Grant
- 2010-08-17 BR BR112012003806A patent/BR112012003806A2/pt not_active Application Discontinuation
- 2010-08-17 AU AU2010284329A patent/AU2010284329B2/en active Active
- 2010-08-17 CA CA2770762A patent/CA2770762A1/en not_active Abandoned
- 2010-08-17 CN CN2010800457286A patent/CN102869385A/zh active Pending
- 2010-08-17 JP JP2012525649A patent/JP2013502218A/ja not_active Withdrawn
- 2010-08-17 EP EP10810508.1A patent/EP2467167B1/en active Active
- 2010-08-17 NZ NZ598557A patent/NZ598557A/xx unknown
- 2010-08-17 WO PCT/US2010/045797 patent/WO2011022427A1/en not_active Ceased
- 2010-08-17 IN IN1984DEN2012 patent/IN2012DN01984A/en unknown
- 2010-08-17 RU RU2012110221/10A patent/RU2012110221A/ru unknown
- 2010-08-17 KR KR1020127007005A patent/KR20120061086A/ko not_active Withdrawn
- 2010-08-17 US US12/858,369 patent/US8252913B2/en active Active
-
2012
- 2012-02-12 IL IL218048A patent/IL218048A0/en unknown
- 2012-03-16 CO CO12046249A patent/CO6531414A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013502218A (ja) | 2013-01-24 |
| AU2010284329B2 (en) | 2015-04-16 |
| IL218048A0 (en) | 2012-04-30 |
| SG178408A1 (en) | 2012-03-29 |
| CN102869385A (zh) | 2013-01-09 |
| WO2011022427A1 (en) | 2011-02-24 |
| ES2655589T3 (es) | 2018-02-20 |
| IN2012DN01984A (enExample) | 2015-07-24 |
| KR20120061086A (ko) | 2012-06-12 |
| NZ598557A (en) | 2013-08-30 |
| US8252913B2 (en) | 2012-08-28 |
| AU2010284329A1 (en) | 2012-03-29 |
| EP2467167B1 (en) | 2017-08-16 |
| EP2467167A1 (en) | 2012-06-27 |
| BR112012003806A2 (pt) | 2016-11-16 |
| MX2012002133A (es) | 2013-02-15 |
| CA2770762A1 (en) | 2011-02-24 |
| CO6531414A2 (es) | 2012-09-28 |
| EP2467167A4 (en) | 2013-12-25 |
| US20110098345A1 (en) | 2011-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7854774B2 (ja) | 第ｘｉｉ因子遺伝子発現を阻害するための組成物および方法 | |
| EP1745062B1 (en) | Improved modulators of coagulation factors | |
| AU2022203170A1 (en) | Compositions and methods for inhibiting gene expression of factor Xll | |
| JP2006521098A5 (enExample) | ||
| TW202334422A (zh) | 抑制血管緊張素原（agt）蛋白表達的組合物和方法 | |
| CN102869385A (zh) | 针对组织因子途径抑制物的适体和其作为出血病症治疗剂的用途 | |
| JP2023093535A (ja) | フォン・ヴィレブランド因子に関連する合併症及び障害の処置のための組成物及び方法 | |
| US20240417739A1 (en) | Compositions and methods for treatment of bleeding disorders | |
| WO2023186056A1 (zh) | 用于抑制补体成分c3蛋白表达的组合物和方法 | |
| JPWO2014080997A1 (ja) | ミッドカインに対するアプタマー及びその用途 | |
| Boţianu et al. | Acquired haemophilia complicated with gastrointestinal bleeding and spontaneous iliopsoas muscle haematoma in a woman with chronic C hepatitis under treatment with pegylated IFN alpha 2a and ribavirin. | |
| CN116478267A (zh) | 可与底物结合的蛋白序列在制备抑制纤维蛋白组装的产品中的应用 | |
| JP6002691B2 (ja) | 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用 | |
| RU2401306C2 (ru) | Аптамерный олигонуклеотид - прямой ингибитор тромбина | |
| JP2025508324A (ja) | プレカリクレイン（ｐｋｋ）タンパク質の発現を阻害するための組成物及び方法 | |
| Oney | Development of novel antidote controlled antithrombotic aptamers | |
| CN118922540A9 (zh) | 前激肽释放酶调节组合物及其使用方法 | |
| CN116723863A (zh) | 用于治疗出血性病症的组合物和方法 |